市場調査レポート

商品コード

軽度認知障害の世界市場：疾患タイプ・年齢・適応症・治療法・地域別の予測 (～2032年)

Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

出版日: 2024年08月28日
発行: Market Research Future
ページ情報: 英文 153 Pages
納期: 即納可能

価格

PDF & Excel (Single User License)

USD 4,950 727,600円

レポートPDF、Excelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Multi User License)

USD 5,950 874,590円

レポートPDF、Excelを同一企業内の最大15名がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。

PDF & Excel (Enterprise License)

USD 7,250 1,065,677円

レポートPDF、Excelを同一企業内のすべての方がご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDF、Excelの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

軽度認知障害の市場規模は、2023年の19億4,000万米ドル、22024年の20億5,000万米ドルから、予測期間中は5.95のCAGRで推移し、2032年には32億5,000万米ドルの規模に成長すると予測されています。

軽度認知障害市場の主な促進要因は、世界的な軽度認知障害の有病率の増加と、軽度認知障害に対する認識の高まりです。多剤併用と併存疾患のコントロールが治療の選択肢を複雑にしており、これが世界市場の成長を鈍化させるとも予測されていますが、軽度認知障害の早期診断に関する技術開発が収益性の高い市場展望をもたらすと予想されています。

地域別インサイト

北米市場は2022年に42.60％で最大の市場シェアを占め、予測期間中は4.97％のCAGRで成長し、2032年にはおよそ13億1,000万米ドルの規模に達すると予測されています。また、アジア太平洋地域は予測期間中6.91%という最速のCAGRで成長すると予測されています。北米の軽度認知障害市場は、今後堅調な伸びが見込まれています。医療インフラへの投資と最新医療ソリューションの認知度の向上が、市場成長をさらに促進すると予測されています。既存企業も新規参入企業も、より良い手術結果に対するニーズの高まりに対応するため、改善された技術を活用し、こうした可能性をつかむ準備を整えています。

欧州市場は、技術の改善、医療費の上昇、軽度認知障害の負担増により、第2位の市場シェアを占めています。ドイツが最大の市場シェアを持ち、英国は欧州でもっとも急激な成長を示すと予測されています。

当レポートでは、世界の軽度認知障害の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

LIST OF TABLES

TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR AMNESTIC MCI, BY REGION, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR NON-AMNESTIC MCI, BY REGION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR CHILD, BY REGION, 2019-2032 (USD BILLION)
TABLE 7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ADULT, BY REGION, 2019-2032 (USD BILLION)
TABLE 8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR GERIATRIC, BY REGION, 2019-2032 (USD BILLION)
TABLE 9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR LEWY BODY DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
TABLE 11 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR PARKINSON'S DISEASE DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
TABLE 12 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ALZHEIMER'S DISEASE, BY REGION, 2019-2032 (USD BILLION)
TABLE 13 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR VASCULAR DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
TABLE 14 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 15 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 16 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY REGION, 2019-2032 (USD BILLION)
TABLE 17 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 18 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR CHOLINESTERASE INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 19 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR BENZODIAZEPINES, BY REGION, 2019-2032 (USD BILLION)
TABLE 20 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR GLUTAMATE INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 21 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ANTIHISTAMINES, BY REGION, 2019-2032 (USD BILLION)
TABLE 22 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MAO INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 23 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR PROTON PUMP INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
TABLE 24 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
TABLE 25 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY REGION, 2019-2032 (USD BILLION)
TABLE 26 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 27 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR COGNITIVE STIMULATION THERAPY, BY REGION, 2019-2032 (USD BILLION)
TABLE 28 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR COGNITIVE BEHAVIOURAL THERAPY (CBT), BY REGION, 2019-2032 (USD BILLION)
TABLE 29 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 30 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 31 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 32 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 34 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 35 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 36 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 37 US MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 38 US MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 39 US MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 40 US MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 41 US MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 42 US MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 43 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 44 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 45 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 46 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 47 CANADA MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 48 CANADA MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 49 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 50 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 51 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 52 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 53 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 54 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 55 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 56 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 57 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 58 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 59 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 60 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 61 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 62 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 63 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 64 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 65 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 66 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 67 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 68 UK MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 69 UK MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 70 UK MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 71 UK MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 72 UK MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 73 UK MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 74 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 75 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 76 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 77 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 78 ITALY MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 79 ITALY MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 80 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 81 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 82 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 83 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 84 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 85 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 86 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 87 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 88 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 89 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 90 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
TABLE 91 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
TABLE 92 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 93 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 94 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 95 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 96 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 97 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 98 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 99 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 100 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 101 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 102 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 103 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 104 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 105 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 106 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 107 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 108 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 109 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 110 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 111 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 112 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 113 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 114 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 115 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 116 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 117 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 118 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 119 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 120 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 121 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 122 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 123 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 124 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 125 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 126 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 127 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 128 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 129 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 130 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 131 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 132 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 133 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 134 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 135 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2019-2032 (USD BILLION)
TABLE 136 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 137 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 138 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 139 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 140 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 141 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 142 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 143 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 144 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 145 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 146 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 147 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 148 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
TABLE 149 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
TABLE 150 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 151 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 152 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
TABLE 153 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
TABLE 154 PUBLIC PLAYERS STOCK SUMMARY
TABLE 155 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 156 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 157 JOHNSON & JOHNSON SERVICES, INC: PRODUCT OFFERED
TABLE 158 PFIZER INC: PRODUCT OFFERED
TABLE 159 NOVARTIS AG: PRODUCT OFFERED
TABLE 160 ABBVIE INC.: PRODUCTS OFFERED
TABLE 161 BIOGEN: PRODUCTS OFFERED
TABLE 162 BIOGEN: KEY DEVELOPMENTS
TABLE 163 EISAI CO., LTD.: PRODCUTS OFFERED
TABLE 164 EISAI CO., LTD.: KEY DEVELOPMENTS
TABLE 165 AUROBINDO PHARMA: PRODCUTS OFFERED
TABLE 166 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 167 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODCUTS OFFERED
TABLE 168 TAJ PHARMACEUTICALS LTD.: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET: STRUCTURE
FIGURE 2 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
FIGURE 6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2022 & 2032 (USD BILLION)
FIGURE 7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY DISEASE TYPE,
FIGURE 8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2022 & 2032 (USD BILLION)
FIGURE 9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY AGE,
FIGURE 10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)
FIGURE 11 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY INDICATION,
FIGURE 12 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2022 & 2032 (USD BILLION)
FIGURE 13 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY TREATMENT,
FIGURE 14 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2022 & 2032 (USD BILLION)
FIGURE 15 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY REGION,
FIGURE 16 NORTH AMERICA MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 19 EUROPE MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 20 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 21 EUROPE MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 22 ASIA-PACIFIC MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2030 (USD BILLION)
FIGURE 23 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2030 (USD BILLION)
FIGURE 24 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 25 REST OF THE WORLD MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2030 (USD BILLION)
FIGURE 26 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2022 & 2030 (USD BILLION)
FIGURE 27 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY REGION,
FIGURE 28 MILD COGNITIVE IMPAIRMENT MARKET PLAYERS: COMPETITIVE ANALSIS,
FIGURE 29 COMPETITOR DASHBOARD: GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
FIGURE 30 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS
FIGURE 32 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 PFIZER INC: SWOT ANALYSIS
FIGURE 34 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 NOVARTIS AG: SWOT ANALYSIS
FIGURE 36 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 ABBVIE INC.: SWOT ANALYSIS
FIGURE 38 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 EISAI CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW
FIGURE 42 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

Product Code: MRFR/HC/9432-CR

Global Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032

Market Overview

The market size for mild cognitive impairment was estimated to be USD 1.94 billion in 2023. The global mild cognitive impairment industry is expected to expand from USD 2.05 billion in 2024 to USD 3.25 billion by 2032, with a compound annual growth rate (CAGR) of 5.95% during the forecast period (2024-2032).

The growing prevalence of mild cognitive impairment around the world, as well as increased awareness of mild cognitive impairment, are the primary drivers of the Mild Cognitive Impairment Market. However, polypharmacy and controlling comorbidities complicate treatment options, which is projected to slow worldwide market growth. Nonetheless, technological developments in the early diagnosis of MCI around the world are expected to provide profitable market prospects. The rising global prevalence of moderate cognitive impairment (MCI) is a primary driver of the global MCI treatment industry.

Marketing Segmentation

Mild Cognitive Impairment Market Segmentation by Disease Type, Amnestic MCI, and Non-Amnestic MCI.

The mild cognitive impairment market segmentation by age comprises child, adult, and geriatric.

The Mild Cognitive Impairment Market has been classified according to indication: Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others.

The Mild Cognitive Impairment Market has been divided into two segments: medicine and therapy.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American mild cognitive impairment market had the greatest market share of 42.60% in 2022 and is expected to reach roughly USD 01.31 billion by 2032, growing at a 4.97% CAGR over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 6.91% over the forecast period. The North American mild cognitive impairment market is expected to increase steadily in the future. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.

Europe's mild cognitive impairment market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increased burden of mild cognitive impairment. Furthermore, the German mild cognitive impairment market is expected to have the biggest market share, with the UK mild cognitive impairment market forecast to be the fastest expanding market in Europe.

The Asia-Pacific mild cognitive impairment market is predicted to develop the fastest from 2024 to 2032, owing to a large patient population, an increasing number of mild cognitive cases, and favorable regulatory regulations. Furthermore, prominent companies in the mild cognitive impairment market are aggressively expanding into this region, propelling the regional market forward. Furthermore, China's mild cognitive impairment market had the greatest market share, while India's mild cognitive impairment market is expected to be the fastest expanding in the Asia-Pacific region.

Major Players

Key players in the mild cognitive impairment market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd. (Japan), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Taj Pharmaceuticals Limited (India).

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELLING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Increasing burden of Mild cognitive impairment across the globe
- 4.2.2 Rising awareness associated with mild cognitive impairment
4.3 RESTRAINTS
- 4.3.1 Polypharmacy and managing comorbidities complicate treatment strategies
4.4 OPPORTUNITY
- 4.4.1 Technological advancements for early diagnosis of MCI

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL MILD COGNITIVE IMPAIRMENT MARKET

6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE

6.1 OVERVIEW
6.2 AMNESTIC MCI
6.3 NON-AMNESTIC MCI

7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE

7.1 OVERVIEW
7.2 CHILD
7.3 ADULT
7.4 GERIATRIC

8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION

8.1 OVERVIEW
8.2 LEWY BODY DEMENTIA
8.3 PARKINSON'S DISEASE DEMENTIA
8.4 ALZHEIMER'S DISEASE
8.5 VASCULAR DEMENTIA
8.6 OTHERS

9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT

9.1 OVERVIEW
9.2 MEDICATION
- 9.2.1 Cholinesterase Inhibitors
- 9.2.2 Benzodiazepines
- 9.2.3 Glutamate Inhibitors
- 9.2.4 Antihistamines
- 9.2.5 Mao Inhibitors
- 9.2.6 Proton Pump Inhibitors
- 9.2.7 Others
9.3 THERAPY
- 9.3.1 Cognitive Stimulation Therapy
- 9.3.2 Cognitive Behavioural Therapy (CBT)

10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 us
- 10.2.2 canada
10.3 EUROPE
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 UK
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 South Korea
- 10.4.5 AUSTRALIA
- 10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
- 10.5.1 Middle East & Africa
- 10.5.2 Latin America

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 product launch / Product approval

12 COMPANY PROFILES

12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 productS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 PFIZER INC
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 productS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 NOVARTIS AG
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 productS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 BIOGEN
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 EISAI CO., LTD.
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 AUROBINDO PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 TAJ PHARMACEUTICALS LTD.
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

軽度認知障害の世界市場：疾患タイプ・年齢・適応症・治療法・地域別の予測 (～2032年)

Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

目次

第1章エグゼクティブサマリー

第2章市場概要

第3章調査手法

第4章市場力学

第5章市場要因分析

第6章世界の軽度認知障害市場：疾患タイプ別

第7章世界の軽度認知障害市場：年齢別

第8章世界の軽度認知障害市場：適応症別

第9章世界の軽度認知障害市場：治療別

第10章世界の軽度認知障害市場：地域別

第11章競合情勢

第12章企業プロファイル

第13章データの引用

LIST OF TABLES

LIST OF FIGURES

Market Overview

Major Players

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE

7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE

8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION

9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT

10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION

11 COMPETITIVE LANDSCAPE

12 COMPANY PROFILES

13 DATA CITATIONS

軽度認知障害の世界市場：疾患タイプ・年齢・適応症・治療法・地域別の予測 (～2032年)

Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

第5章 市場要因分析

第6章 世界の軽度認知障害市場：疾患タイプ別

第7章 世界の軽度認知障害市場：年齢別

第8章 世界の軽度認知障害市場：適応症別

第9章 世界の軽度認知障害市場：治療別

第10章 世界の軽度認知障害市場：地域別

第11章 競合情勢

第12章 企業プロファイル

第13章 データの引用

LIST OF TABLES

LIST OF FIGURES

Market Overview

Major Players

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE

7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE

8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION

9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT

10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION

11 COMPETITIVE LANDSCAPE

12 COMPANY PROFILES

13 DATA CITATIONS

第1章エグゼクティブサマリー

第2章市場概要

第3章調査手法

第4章市場力学

第5章市場要因分析

第6章世界の軽度認知障害市場：疾患タイプ別

第7章世界の軽度認知障害市場：年齢別

第8章世界の軽度認知障害市場：適応症別

第9章世界の軽度認知障害市場：治療別

第10章世界の軽度認知障害市場：地域別

第11章競合情勢

第12章企業プロファイル

第13章データの引用